Results 191 to 200 of about 35,569 (305)

The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study. [PDF]

Ther Adv Musculoskelet Dis
Israel A, Hassan F, Merzon E, Kurtam J, Awad J, Assalia M, Green I, Vinker S, Naffaa ME.   +8 more
europepmc   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock, Chantal Mathieu, Joshua Buron Feinberg, Priyanka Rao, Cathrine Scavenius, Alice Y. Y. Cheng   +5 more
wiley   +1 more source

Association of glucagon-like peptide-1 receptor agonist use with patient-reported outcomes after lumbar decompression or fusion. [PDF]

N Am Spine Soc J
Parker J, Brennan J, Johnson A, Peterman M, Patton C, Turcotte J.   +5 more
europepmc   +1 more source

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. [PDF]

Diabetes Obes Metab
Vilsbøll T, Stellfeld M, Aroda VR, Dandanell S, David JP, Kristiansen CTP, Rasmussen S, Roberts FL, Hegedüs L.   +8 more
europepmc   +1 more source

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT‐J Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the impact of tirzepatide on health‐related quality of life (HR‐QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT‐J trial. Materials and Methods Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle ...
Hiroaki Masuzaki, Hirotaka Nagashima, Tomotaka Shingaki, Tomonori Oura, Ichiro Tatsuno   +4 more
wiley   +1 more source

Association of glucagon-like peptide-1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes. [PDF]

J Diabetes Investig
Yu YT, Lee YC, Fang YW, Hsieh WH, Tsai MH.   +4 more
europepmc   +1 more source

Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Prediabetes and left ventricular hypertrophy (LVH) are common risk factors in adults with hypertension. Whether their coexistence, particularly in the presence of subclinical myocardial injury or stress (malignant LVH), confers a heightened stroke risk is unknown.
Arnaud D. Kaze, Stephen P. Juraschek, Jordana B. Cohen, Siddharth Singh, Chiadi E. Ndumele, Christie M. Ballantyne, Jarrett D. Berry, Justin B. Echouffo‐Tcheugui   +7 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. [PDF]

Arthritis Rheumatol
Haberman RH, Rice AL, Chen K, Scher U, Thib S, Scher JU, Eder L.   +6 more
europepmc   +1 more source

Dual Glucagon and GLP‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
Elif I. Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla Martinez, Anita M. Hennige, Corinna Schoelch   +5 more
wiley   +1 more source

Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases. [PDF]

Dermatol Ther (Heidelb)
Kwiek B, Sieczych J, Łukowska K, Ambroziak M.   +3 more
europepmc   +1 more source